HOME >> BIOLOGY >> NEWS
Differences in gene usage dramatically change bacteria's 'lifestyles'

nella and E. coli share the gene for an antibiotic resistance regulatory protein called PmrA. By controlling when other proteins are produced, PmrA can make the cell wall more resistant to damage from the antibiotic polymyxin B. The PmrA protein normally activates in response to high iron levels.

In a paper recently published in Genes and Development, Groisman's lab established that another protein, PmrD, also can activate PmrA in response to low magnesium levels.

In the new study, Groisman's lab discovered that E. coli has a different version of PmrD that is unable to turn on the PmrA protein in response to low magnesium.

"We're not really sure what the significance of low magnesium is, but there are some indications that it may be important to the bacteria's ability to survive in white blood cells or outside of the host in soil or water," Groisman says.

When scientists transplanted the Salmonella form of PmrD into E. coli, the bacteria gained the ability to resist polymyxin B in low magnesium environments.

Based on data still to be published, Groisman suspects that many other aspects of microbial lifestyle are affected by differences in regulation of identical genes.

He notes that the idea of different organisms making altered use of the same genes sprang from recent analyses of the human genome.

"Humans not only appear to have far fewer genes than expected, there also seem to be fewer genes that are unique to human DNA than anticipated," Groisman explains.

In addition to instructions for building proteins, DNA contains stretches of code that affect when genes are turned on and off. As life becomes more complex over the course of evolution, Groisman explains, these regulatory sections appear to take up larger portions of the DNA, allowing genes to be turned on and off in ways that are more intricately responsive to the environment and other factors.

Human DNA, Groisman speculates, may be hea
'"/>

Contact: Michael Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
29-Nov-2004


Page: 1 2 3

Related biology news :

1. Photos reveal first tool usage in wild gorillas
2. Jefferson scientists patent dramatically improves
3. Growing nerve cells in 3-D dramatically affects gene expression
4. Plant size morphs dramatically as scientists tinker with outer layer
5. Lack of a key enzyme dramatically increases resistance to sepsis
6. Simple idea to dramatically improve dengue vaccinations
7. Moderate lifetime reductions in LDL cholesterol dramatically reduce risk of heart disease
8. Ownership of Southern forestland dramatically changing
9. UF Researcher: Global warming dramatically changed ancient forests
10. Caloric restriction wont dramatically extend life span in humans: UCLA research
11. New miniaturised chip dramatically reduces time taken for DNA analysis

Post Your Comments:
(Date:5/10/2015)... , May 11, 2015 Fingerprint ... sensors FPC1025 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... will be used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK for ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
(Date:5/5/2015)... 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, reminds investors and media that  Mr. ... presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series of ... themed Global Fraud: Where is the Trust in Cyberspace? ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... 20, 2015 Veracyte, Inc . ... demonstrating the ability of the company,s molecular classifier ... other interstitial lung diseases (ILDs) using samples obtained ... to help thousands of patients avoid invasive, risky ... diagnosis – a frequent challenge for physicians and ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) has announced ... Outlook 2020 " report to their offering. ... medicine is expected to have huge marketing potential. Presently, ... the growth of deregulated organs. Several therapeutic molecules are ... form new tissue or sometimes organ transplant is required. ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: